Table 1.
Baseline characteristics of patients stratified by race
| Covariates | Overall, n=9422 | Race | |||
|---|---|---|---|---|---|
| White, n=7084 | Black, n=1854 | Other, n=484 | P Value | ||
| Demographics and socioeconomic variables | |||||
| Sex: women, n/N (%) | 3097/9422 (33) | 2127/7084 (30) | 820/1854 (44) | 150/484 (31) | <0.001 |
| Age, yr, N, median, (Q1, Q3) | 9422, 63 (54, 72) | 7084, 64 (55, 73) | 1854, 60 (51, 69) | 484, 60 (52, 68) | <0.001 |
| Marital status, n/N (%) | <0.001 | ||||
| Married or life-partner | 6355/9377 (68) | 5013/7051 (71) | 1015/1848 (55) | 327/478 (68) | |
| Othera | 3022/9377 (32) | 2038/7051 (29) | 833/1848 (45) | 151/478 (32) | |
| Median household income scaled in US$1000, N, median, (Q1, Q3) | 8048, 45 (33, 61) | 6123, 46 (36, 63) | 1528, 37 (26, 48) | 397, 37 (27, 58) | <0.001 |
| Comorbidities | |||||
| Tobacco use, n/N (%) | 4244/9422 (45) | 3247/7084 (46) | 782/1854 (42) | 215/484 (44) | 0.02 |
| BMI, kg/m2, N, median, (Q1, Q3) | 9384, 29 (25, 33) | 7059, 29 (25, 32) | 1842, 29 (26, 34) | 483, 28 (25, 32) | <0.001 |
| Pre-existing CVD, n/N (%) | |||||
| Congestive heart failure | 1592/9316 (17) | 1201/7006 (17) | 318/1835 (17) | 73/475 (15) | 0.58 |
| Cerebrovascular disease | 802/9422 (9) | 614/7084 (9) | 146/1854 (8) | 42/484 (9) | 0.55 |
| Myocardial infarction | 4631/9422 (49) | 3376/7084 (48) | 990/1854 (53) | 265/484 (55) | <0.001 |
| PVD | 756/9422 (8) | 586/7084 (8) | 131/1854 (7) | 39/484 (8) | 0.24 |
| Hyperlipidemia, n/N (%) | 5866/9422 (62) | 4542/7084 (64) | 1040/1854 (56) | 284/484 (59) | <0.001 |
| Diabetes, n/N (%) | 2804/9422 (30) | 1921/7084 (28) | 715/1854 (39) | 168/484 (35) | <0.001 |
| Diabetes with end organ damage, n/N (%) | 159/9422 (1.7) | 111/7084 (1.6) | 40/1854 (2.2) | 8/484 (1.7) | 0.21 |
| HBA1c, %, N, median, (Q1, Q3) | 3440, 6.3 (5.8, 7.4) | 2441, 6.2 (5.7, 7.2) | 810, 6.5 (5.9, 8.1) | 189, 6.3 (5.8, 7.6) | <0.001 |
| Baseline eGFR, ml/min per 1.73 m2, N, median, (Q1, Q3) | 9422, 74 (57, 89) | 7084, 73 (56, 88) | 1854, 78 (58, 97) | 484, 78 (60, 93) | <0.001 |
| Medication use, n/N (%) | |||||
| RAAS inhibitors | 4352/9422 (46) | 3193/7084 (45) | 929/1854 (50) | 230/484 (48) | <0.001 |
| Diuretics | 1976/9422 (21) | 1428/7084 (20) | 470/1854 (25) | 78/484 (16) | <0.001 |
| NSAIDs | 4920/9422 (52) | 3625/7084 (51) | 1040/1854 (56) | 255/484 (53) | <0.001 |
| Indication for PCI, n/N (%) | |||||
| Acute coronary status | 6328/9422 (67) | 4632/7084 (65) | 1343/1854 (72) | 353/484 (73) | <0.001 |
| STEMI | 1987/9422 (21) | 1403/7084 (20) | 473/1854 (26) | 111/484 (23) | |
| Non-STEMI | 1682/9422 (18) | 1174/7084 (17) | 394/1854 (21) | 114/484 (24) | |
| MI unspecified | 18/9422 (0.2) | 15/7084 (0.2) | 1/1854 (0.2) | 2/484 (0.4) | |
| Unstable angina | 2641/9422 (28) | 2040/7084 (29) | 475/1854 (26) | 126/484 (26) | |
| Peri-procedural AKI prophylaxis, n/N (%) | |||||
| IV fluid administration | 9047/9422 (96) | 6805/7084 (96) | 1780/1854 (96) | 462/484 (96) | 0.15 |
| N-Acetylcysteine use | 153/9422 (2) | 117/7084 (2) | 30/1854 (2) | 6/484 (1) | 0.63 |
| PCI procedural characteristics | |||||
| yr of index PCI, n/N (%) | 0.003 | ||||
| 2003–2005 | 4022/9422 (43) | 3043/7084 (43) | 746/1854 (40) | 233/484 (48) | |
| 2006–2008 | 2515/9422 (27) | 1864/7084 (26) | 510/1854 (28) | 141/484 (29) | |
| 2009–2011 | 1735/9422 (18) | 1308/7084 (19) | 360/1854 (19) | 67/484 (14) | |
| 2012–2013 | 1150/9422 (12) | 869/7084 (12) | 238/1854 (13) | 43/484 (9) | |
| PCI setting: nonelective | 3027/9422 (32) | 2179/7084 (31) | 682/1854 (37) | 166/484 (34) | <0.001 |
| Contrast volume, ml, N, median, (Q1,Q3) | 9353, 250 (190, 335) | 7030, 250 (190, 335) | 1843, 240 (180, 325) | 480, 250 (190, 325) | 0.005 |
| No. of stents placed, n/N (%) | 0.07 | ||||
| 0 | 326/9378 (4) | 243/7043 (4) | 68/1852 (4) | 15/483 (3) | |
| 1 | 5509/9378 (59) | 4077/7043 (58) | 1149/1852 (62) | 283/483 (59) | |
| 2 | 2285/9378 (24) | 1755/7043 (25) | 410/1852 (22) | 120/483 (25) | |
| 3 | 842/9378 (9) | 638/7043 (9) | 153/1852 (8) | 51/483 (11) | |
| 4 | 305/9378 (3) | 244/7043 (4) | 50/1852 (3) | 11/483 (2) | |
| 5–8 | 111/9378 (1) | 86/7043 (1) | 22/1852 (1) | 3/483 (1) | |
| Systolic BP, mm Hg, N, median, (Q1, Q3) | 8874, 141 (127, 160) | 6670, 140 (126, 158) | 1754, 146 (131, 166) | 450, 141 (126, 159) | <0.001 |
| Diastolic BP, mm Hg, N, median, (Q1, Q3) | 8775, 81 (72, 90) | 6598, 80 (72, 89) | 1730, 85 (76, 95) | 447, 82 (74, 91) | <0.001 |
BMI, body mass index; CVD, cardiovascular disease; PVD, peripheral vascular disease; STEMI, ST-elevation myocardial infarction; NSAIDs, nonsteroidal anti-inflammatory drugs; IV, intravenous.
a
Other includes single, separated, divorced, widowed, or unknown.